Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation & Amortization (CF) (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Depreciation & Amortization (CF) data on record, last reported at $428000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 10.83% year-over-year to $428000.0; the TTM value through Dec 2025 reached $2.0 million, up 7.76%, while the annual FY2025 figure was $2.0 million, 7.76% up from the prior year.
  • Depreciation & Amortization (CF) reached $428000.0 in Q4 2025 per CCCC's latest filing, down from $460000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $615000.0 in Q2 2025 and bottomed at $300000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $441000.0, with a median of $447500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 33.48% in 2022, then skyrocketed 81.67% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $323000.0 in 2021, then surged by 61.3% to $521000.0 in 2022, then decreased by 17.47% to $430000.0 in 2023, then grew by 11.63% to $480000.0 in 2024, then dropped by 10.83% to $428000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $428000.0 in Q4 2025, $460000.0 in Q3 2025, and $615000.0 in Q2 2025.